Krissy Choi, DO
Rheumatology · Summit, NJNPI 1871864371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 642 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 642 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Novartis$1K
- Pfizer$994
- Johnson & Johnson$730
- UCB, Inc.$424
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,32397%
- Education$3123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 138 | $1,901 |
| Amgen(2 entities) | 120 | $1,662 |
| Novartis | 83 | $1,371 |
| Pfizer | 84 | $994 |
| Johnson & Johnson(2 entities) | 39 | $730 |
| UCB, Inc. | 24 | $424 |
| GSK | 15 | $317 |
| Sanofi | 19 | $315 |
| Lilly USA, LLC | 18 | $258 |
| AstraZeneca | 17 | $255 |
| E.r. Squibb & Sons, L.L.C. | 17 | $249 |
| Aurinia Pharma U.S., Inc. | 12 | $202 |
| Genentech USA, Inc. | 5 | $132 |
| Organon | 5 | $86 |
| Pacira Therapeutics, Inc. | 5 | $76 |
| Sobi, Inc | 5 | $74 |
| Boehringer Ingelheim | 5 | $72 |
| ANI Pharmaceuticals, Inc. | 4 | $71 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| Ferring Pharmaceuticals Inc. | 3 | $49 |
| Bristol Myers Squibb | 3 | $44 |
| Bioventus LLC | 2 | $43 |
| Radius Health, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $28 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Alvogen Inc | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Sandoz | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$122
How this compares
$9,635 in reported general payments places this provider in the 80th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 47 | $378,332 |
| Cosentyx Sensoready PenSecukinumab | 15 | $221,366 |
| EnbrelEtanercept | 24 | $193,436 |
| Humira(Cf) PenAdalimumab | 24 | $158,601 |
| Orencia ClickjectAbatacept | 23 | $153,914 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $71,533 |
| OrenciaAbatacept/Maltose | 13 | $39,311 |
| Hydroxychloroquine Sulfate | 140 | $6,882 |
| MethotrexateMethotrexate Sodium | 216 | $5,521 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $5,262 |
| Mycophenolate Mofetil | 25 | $3,916 |
| Leflunomide | 26 | $2,298 |
| Colchicine | 19 | $959 |
| Prednisone | 144 | $935 |
| Allopurinol | 61 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $1,662 | $193,43624 claims |
| UCB, Inc.Cimzia (2 Pack) | $424 | $71,53313 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $249 | $39,31113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Summit
- Jeffrey GreenbergSummit$399K
- Elliot RosensteinSummit$101K
- Neil KramerSummit$37K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.